Wonder Topical Spray for premature ejaculation

Male erectile failure is a common problem not only in North America but worldwide. For decades research has been ongoing to discover a pill or cream that can at least maintain erection and help males who suffer from premature ejaculation. Recent reports from the first US trials on a formulation of a spray anesthetic indicate that drug, Tempe, may have some promise. 

The anesthetic is sprayed on the penis and recent studies show that it increases the time to ejaculation by as much as five hundred percent. Researchers claim that this is by far the best drug ever for premature ejaculation.

Premature ejaculation is a common problem in males aged 18-60 and affects as many as one in 3 men. These numbers experts say may even be much higher as many men do not always come forward because of fear of embarrassment.

In men who have erectile dysfunction, premature ejaculation is claimed to be even more common. While many treatments have been devised for this annoying social problem, none has been effective in the long term. Previously available creams took nearly 45-60 minutes to work. More over the individuals had to wear a condom to prevent transmitting the anesthetic to the partner.

Now there is news for individuals suffering from premature ejaculation. Pharmaceutical company Plethora Solutions of London, England and Sciele Pharma Inc. of Atlanta have developed an anesthetic spray, called PSD502 or Tempe, that contains Lidocaine and prilocaine which is released as an aerosol spray. The drug is simply sprayed on the penis prior to sexual intercourse.

The present trial was held in 38 US medical centers and had 256 men across the USA, Canada and Poland. Prior to the study, these patients had an average duration of intercourse of 36 seconds.

Two-thirds of the participants used PSD502 and the rest were given a placebo spray.

Dr. Michael G. Wyllie of Plethora presented his findings at a recent Sexual Medicine Society meeting in San Diego. The results showed that men who received the drug had an increased intercourse time to an average of 156 seconds, compared with an increase of only 48 seconds in the placebo group. These benefits continued for several months during the study. Moreover, both men and women reported superior fulfillment with their sexual experiences. Other than an occasional numbing sensation felt by the female, no other adverse effects were observed.  Since the Europeans have also showed similar results there are now plans to undertake more studies and get FDA approval.